We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Chemomab Therapeutics Ltd (CMMB) ADR EACH REPR 20 ORD SHS SPON

Sell:$1.62 Buy:$1.79 Change: $0.05 (3.13%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$1.62
Buy:$1.79
Change: $0.05 (3.13%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$1.62
Buy:$1.79
Change: $0.05 (3.13%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Contact details

Address:
Kiryat Atidim, Building 7
TEL AVIV-YAFO
6158002
Israel
Telephone:
+972 (7) 73310156
Website:
https://www.chemomab.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CMMB
ISIN:
US16385C1045
Market cap:
$30.92 million
Shares in issue:
377.13 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Adi Mor
    Chief Executive Officer, Director
  • Sigal Fattal
    Chief Financial Officer
  • Matthew Frankel
    Chief Medical Officer, Vice President - Drug Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.